ARTES Biotechnology and Bio Farma announce collaboration in vaccine development

ARTES and Bio Far­ma announced today to join forces for the devel­op­ment and man­u­fac­tur­ing of vac­cine can­di­dates. The agreed col­lab­o­ra­tion involved the strength of both part­ners. ARTES is spe­cial­ized in cell line and process devel­op­ment, VLP based vac­cines as well as in tech­nol­o­gy trans­fer for phar­ma­ceu­ti­cal­ly rel­e­vant pro­duc­tion process­es where­as Bio Far­ma is involved in the man­u­fac­tur­ing of vac­cines, serum and oth­er bio­log­i­cal prod­ucts for the Indone­sian domes­tic and inter­na­tion­al mar­kets.

Under this com­mit­ment a first agree­ment for VLP based vac­cine tech­nol­o­gy trans­fer was signed on July 1st in Ban­dung, Indone­sia.

We are extreme­ly delight­ed about the mutu­al­ly agreed col­lab­o­ra­tion. Bio Far­ma is a strong and reli­able phar­ma­ceu­ti­cal part­ner and the only vac­cine and anti­s­era pro­duc­er for humans in Indone­sia. We are more than con­fi­dent, that we along with Bio Far­ma will devel­op vac­cines high­ly rel­e­vant for the Indone­sian and neigh­bor­ing mar­kets. We expect that espe­cial­ly devel­op­ments based on our Metavax® tech­nol­o­gy will con­tribute to Bio Farma´s vac­cine port­fo­lio”, Dr. Michael Pio­ntek, founder and man­ag­ing direc­tor of ARTES Biotech­nol­o­gy.

Metavax® is a patent pro­tect­ed VLP tech­nol­o­gy, based on mod­i­fi­ca­tions to duck hepati­tis B virus. The approach elic­its a high­ly potent immune response and there­fore a broad­er pro­tec­tion than the cur­rent­ly avail­able VLP approach­es.
ARTES´Metavax®platform is suit­able for the devel­op­ment and pro­duc­tion of safe and cost-effec­tive vac­cines.

Mean­while, Gov­ern­ment of Indone­sia, rep­re­sent­ed by Min­istry of Health, Min­istry of Edu­ca­tion and Cul­ture and Min­istry of Research and Tech­nol­o­gy, ful­ly sup­ports this part­ner­ship and will assist in aspects of pol­i­cy to accel­er­ate the devel­op­ment of vac­cines in Indone­sia. The com­mit­ment is deliv­ered at the Nation­al Vac­cine Research Forum, on 2–3 July 2013 in Jakar­ta.

ARTES Biotechnology and Midas Pharma signed Cooperation Contract

ARTES announced the col­lab­o­ra­tion with Midas for strate­gic mar­ket­ing oppor­tu­ni­ties. Aim of the coop­er­a­tion is the find­ing of suit­able part­ners for defined phar­ma­ceu­ti­cals projects like vac­cine and phar­ma­ceu­ti­cal tar­get devel­op­ment or trans­fer of Biosim­i­lar process­es.

ARTES is spe­cial­ized in micro­bial cell line and process devel­op­ment as well as in tech­nol­o­gy trans­fer for phar­ma­ceu­ti­cal indus­try where­as Midas is an inde­pen­dent mar­ket­ing and dis­tri­b­u­tion com­pa­ny, which sup­ports clients in find­ing poten­tial part­ners and mar­kets.

We are con­fi­dent, that we could, togeth­er with Midas’ world­wide rep­re­sen­ta­tives, break into new mar­kets. Espe­cial­ly our vac­cine devel­op­ment plat­form Metavax® has strong capa­bil­i­ties. The Metavax® plat­form is suit­able for the devel­op­ment and pro­duc­tion of cost-effec­tive vac­cines and there­fore inter­est­ing for mar­kets where price is an issue”, Dr. Melanie Pio­ntek, Busi­ness Devel­op­ment Direc­tor of ARTES point­ed out. “The high­ly expand­ed net­work of Midas will open for us new oppor­tu­ni­ties cur­rent­ly in regions where we not yet in. We are very pleased that, with Midas, we have been able to acquire a very com­pe­tent and reli­able part­ner.”

ARTES Biotechnology issued New Patent in Australia for VLP Technology

ARTES Biotech­nol­o­gy spe­cial­ized in micro­bial cell line and process devel­op­ment as well as in tech­nol­o­gy trans­fer for phar­ma­ceu­ti­cal indus­try is pleased to announce the issuance of a new patent for their VLP plat­form. The patent will fur­ther strength­en the Metavax® plat­form of the com­pa­ny. In com­bi­na­tion with the expres­sion plat­form Hansenu­la Metavax® is a unique tool for the devel­op­ment of afford­able, safe and effec­tive vac­cines.
“Our intel­lec­tu­al prop­er­ty strat­e­gy is to pro­vide mul­ti­ple lay­ers of pro­tec­tion for our tech­nol­o­gy plat­form port­fo­lio. We believe that this new patent will have addi­tion­al rein­force­ment to our exist­ing patent estate and for our ser­vice we offer clients for vac­cine devel­op­ment,” said Dr. Melanie Pio­ntek, Busi­ness Devel­op­ment Direc­tor of ARTES.

New website!

ARTES has launched a new web­site, incor­po­rat­ing new con­tent to give a bet­ter view on the cur­rent busi­ness and added offer.

The new site espe­cial­ly fea­tures an overview of ARTES’ busi­ness expan­sion in tech­nol­o­gy trans­fer and its Metavax® approach for VLP-based vac­cine devel­op­ment.

Strategic cooperation between ARTES Biotechnology and PAC

Artes and PAC join forces and com­bine their tech­nolo­gies and know-how.

ARTES Biotech­nol­o­gy spe­cial­izes in recom­bi­nant pro­tein pro­duc­tion, process devel­op­ment in micro­bial expres­sion sys­tems and is a tech­nol­o­gy provider for phar­ma­ceu­ti­cal process­es, while PAC (Peschek Ana­lyt­ic Con­sult­ing) is high­ly skilled in the field of pro­tein analy­sis and qual­i­ty con­trol. Togeth­er with PAC, ARTES will now prospec­tive­ly offer analy­sis of prod­uct qual­i­ty con­trol along side deter­mi­na­tion and quan­tifi­ca­tion of by-prod­ucts and/or process relat­ed resid­u­als. The method analy­sis port­fo­lio of PAC allows ARTES to offer method devel­op­ment and val­i­da­tion in accor­dance with GMP guide­lines in the fol­low­ing ana­lyt­i­cal meth­ods as HPLC-UV/DAD, Mass Spec­trom­e­try Ion Trap (LC-ESI/APCI MS/MS), Mass spec­trom­e­try Quadru­pole (LC-ESI-MS), Gas Chro­matog­ra­phy-Mass Spec­trom­e­try, Cap­il­lary Elec­trophore­sis, Dynam­ic Light Scat­ter­ing and Elec­tron Microscopy.

Strategic collaboration deal for vaccine development

ARTES Biotech­nol­o­gy, spe­cial­ized in recom­bi­nant pro­tein pro­duc­tion and process devel­op­ment in micro­bial expres­sion sys­tems, start­ed a devel­op­ment col­lab­o­ra­tion for two vac­cines togeth­er with glob­al bio­phar­ma-ceu­ti­cal com­pa­ny Cru­cell. Cru­cell is focused on the research & devel­op­ment, pro­duc­tion and mar­ket­ing of vac­cines and anti­bod­ies against infec­tious dis­ease world­wide.

Aim of the long-term research coop­er­a­tion is a new-prod­uct devel­op­ment on the basis of ARTES’ virus like par­ti­cle (VLP) and the well-estab­lished Hansenu­la poly­mor­pha expres­sion sys­tem fit­ting to Crucell’s vac­cine port­fo­lio. The Hansenu­la sys­tem is the pre­ferred tech­nol­o­gy for afford­able mass vac­ci­na­tion and is rec­om­mend­ed by the WHO for hepati­tis B vac­ci­na­tion cam­paigns. In com­bi­na­tion, the unique yeast based VLP approach builds a new and very eco­nom­i­cal approach to low-cost mass pro­duc­tion of safe and effec­tive vac­cines.

Under the terms of the long-term research col­lab­o­ra­tion ARTES is respon­si­ble for deliv­ery of the pro­duc­tion cell lines and process­es to Cru­cell.

ARTES and NL join in a strategic collaboration and co-marketing alliance

ARTES, spe­cial­ized in recom-binant pro­tein pro­duc­tion and process devel­op­ment from yeast expres­sion sys­tems and the US based com­pa­ny NL Biotech-nolo­gies, own­er and spe­cial­ized in cer­tain tech-nolo­gies for pro­duc­tion of vac­cines and diag­nos­tic pro­teins start­ed a strate­gic col­lab­o­ra­tion.

With sign­ing this col­lab­o­ra­tion agree­ment the two com­pa­nies com­bine their know-how and tech­nolo­gies in yeast expres-sion, process and vac­cine devel­op­ment. The direct and notice­able aim is the mar­ket­ing of effi­cient and cost effec­tive vac­cines and diag­nos­tics pro­teins. The first prod­uct that is avail­able right from the start is a Hansenu­la poly­mor­pha derived Hepati­tis E vac­cine. Proof-of-prin­ci­ple and ani­mal stud­ies (mice and macaques) have been done and shown very good result and high immune answers.

The Hepati­tis E trans­mis­sion is a per­son-to-per­son one, nor­mal­ly trig­gered to the fecal-oral route. Infec­tions occur because of con­sump­tion of con­t­a­m­i­nat­ed water and inges­tion of raw or uncooked food – there­fore it is a dis­ease most com­mon in devel­op­ing coun­tries,“ Vitaly Gra­novskiy, man­ag­ing direc­tor of NL car­ried out. And Dr. Michael Pio­ntek, man­ag­ing direc­tor of ARTES added, ”With the Hepati­tis E process we have anoth­er reli­able and cost-effi­cient VLP-based pro­duc­tion process in our port­fo­lio. Like for HepB and avian flu, the man­u­fac­tur­ing costs for this vac­cine are low because of the effec­tive tech­nol­o­gy behind. In our mind, it should be an inter-est­ing process par­tic­u­lar for devel­op­ing coun­tries. “

The part­ners are now look­ing for com­pa­nies to out-license the process.

New Scientific Board Member

Prof. PhD David Ander­son
Bur­net Insti­tute, Mel­bourne, Aus­tralia, Deputy Direc­tor, Bur­net Senior Prin­ci­pal Fel­low.

Pro­fes­sor Ander­son is an expert in Micro­bi­ol­o­gy and Mol­e­c­u­lar Virol­o­gy. He has focused his work on under­stand­ing the struc­ture and assem­bly of hepati­tis virus­es, and the use of this infor­ma­tion to design bet­ter diag­nos­tics, vac­cines and antivi­ral ther­a­pies for con­trol of major viral infec­tions of man. Pro­fes­sor Ander­son has pub­lished more than 60 orig­i­nal research papers and invit­ed chap­ters, and has been invit­ed to speak on orig­i­nal research work at numer­ous nation­al and inter­na­tion­al sci­en­tif­ic meet­ings. He has been active in trans­la­tion of research into prac­ti­cal out­comes through com­mer­cial ven­tures and aca­d­e­m­ic col­lab­o­ra­tions and is an inven­tor on 10 patent fam­i­lies.

We are real­ly proud to wel­come Pro­fes­sor Ander­son as our new board mem­ber and we are pleased that he will sup­port ARTES. We are look­ing for­ward to a suc­cess­ful rela­tion­ship.

BIO 2011, Washington DC

Meet us at the part­ner­ing “Busi­ness Forum” event of the Bio Inter­na­tion­al Con­ven­tion 2011 in Wash­ing­ton DC or con­tact us direct­ly for a per­son­al meet­ing!

The Bio 2011 is tak­ing place from June 27 — 30.
Go to BIO web­site

ARTES steps further into the vaccine business by acquiring Anavax

ARTES Biotech­nol­o­gy announces today the acquire­ment of the ANAVAX virus-like par­ti­cle (VLP) tech­nol­o­gy from Select Vac­cines Ltd. ANAVAX is a patent-pro­tect­ed VLP tech­nol­o­gy that can be applied to the pre­ven­tion of sev­er­al infec­tious dis­eases.

With the com­bi­na­tion of two excel­lent tech­nol­o­gy plat­forms, ANAVAX and the Hansenu­la expres­sion sys­tem, ARTES has posi­tioned itself as a unique part­ner for the vac­cine indus­try.

The ANAVAX VLP plat­form has already been applied to the devel­op­ment of adju­vant-free vac­cines against avian and swine flu, malar­ia and HIV. Hansenu­la is the pre­ferred tech­nol­o­gy for afford­able mass vac­ci­na­tion and is rec­om­mend­ed by the WHO for hepati­tis B vac­ci­na­tion cam­paigns. Togeth­er, the plat­forms build a new approach to low-cost mass pro­duc­tion of safe and effec­tive vac­cines. ARTES’ busi­ness plan is to enhance its posi­tion as a pre­ferred devel­op­ment part­ner for vac­cine man­u­fac­tur­er.